



## PROFESSIONAL IDENTITY IN ACTION: MY HOA LY'S JOURNEY TO LEADERSHIP

We're excited to share a standout essay from the 2024 GMDP Academy cohort.

My Hoa Ly began as a doctor's assistant at an international clinic in Vietnam, providing Vietnamese translations for patients. Now, as a regional project manager at Pfizer, she reflects on how diverse experiences and continuous learning shaped her professional identity in medicines development.

Continue to page 2 to read more of her insights.

### TABLE OF CONTENTS

Professional Identity in Action: My  
Hoa Ly's Journey • P. 2

Now Enrolling: Fall 2025 GMDP  
Academy Modules • P. 3

Bringing CAR-T Closer: UAE  
Advances Partnership • P. 4

Burnout Isn't Inevitable: Thriving  
as a Pharma Leader • P. 4

Navigating the Life Sciences Job  
Market in 2025 • P. 5

AI-Discovered Rentosertib  
Advances to Phase 2a • P. 5

EU Pharma Reform: What the 2025  
Pharma Package Means • P. 6

Powering Progress with Principles  
• P. 6

Safeguarding Science: Module 5  
Starting Soon • P. 7

# PROFESSIONAL IDENTITY IN ACTION: REFLECTIONS ON LEADERSHIP AND GROWTH BY MY HOA LY



In 2018, a significant milestone in my career occurred when I joined Pfizer Vietnam. Initially, I worked as a reviewer for local promotional materials, leveraging my scientific background and critical thinking skills. This position was a turning point, as it provided me with the opportunity to work in a dynamic and fast-paced environment. I was able to collaborate with colleagues from around the world, which broadened my perspective and enhanced my professional identity.

Currently, I serve as a regional project manager for the Emerging Markets at Pfizer, a role that has further solidified my professional identity and sense of purpose. In this position, I navigate the complexities of a VUCA (Volatile, Uncertain, Complex, and Ambiguous) environment, which has sharpened my problem-solving abilities and adaptability. Working with a diverse team has allowed me to apply my skills in stakeholder management and communication, areas that my manager has encouraged me to develop further.

My manager's support has been instrumental in my professional growth. She has provided valuable feedback and encouraged me to pursue continuous learning opportunities. One such opportunity was enrolling in the GMDP Academy's Certification in Medicines Development Program for the 2024 cohort. This program has been transformative, offering a comprehensive overview of critical thinking and professional skills necessary for leadership in the pharmaceutical industry.



My Hoa Ly is a Medical Communications and Content Senior Manager at Pfizer. She leads the development and repurposing of high-quality scientific content across Emerging Markets. Based in Ho Chi Minh City, Vietnam, she enjoys traveling and collecting stamps, postcards, and fridge magnets.

Click [here](#) to read her complete essay.

## MODULE 7: LEADERSHIP IN MEDICINES DEVELOPMENT

**Dates:** September 29 – November 21, 2025

**Tuition:** \$3,000 USD

**Weekly Commitment:** 3–5 hours

**Final Assessment Due:** December 1, 2025

Build confidence and competence in your leadership style through interactive webinars and real-world application. Topics include courageous leadership, thought leadership, change management, and resilience. The module culminates in a personalized Leadership Action Plan.

## MODULE 8: DIGITAL TECHNOLOGY IN MEDICINES DEVELOPMENT

**Dates:** September 29 – November 9, 2025  
(Orientation begins Sept 22)

**Tuition:** \$3,000 USD


**Weekly Commitment:** ~5 hours

Learn how digital tools are reshaping R&D, clinical trials, communication, regulation, and patient engagement. This 8-lesson module includes 2 expert-led webinars and covers topics such as digital ethics, risk management, emerging technology, and patient-centered design.



## NOW ENROLLING

- 100% online and globally accessible
- World-class speakers and interactive learning
- Certificate of Completion from GMDP Academy
- Perfect for professionals in Medical Affairs, R&D, Regulatory, Clinical, and Digital Health

 Apply by September 15, 2025 to reserve your seat and lead the future of pharma.

 [Start Your Application](#)

## BRINGING CAR-T CLOSER: UAE PARTNERSHIP ADVANCES EQUITABLE ACCESS TO CELL THERAPIES

A new partnership between Burjeel Holdings and U.S. nonprofit Caring Cross is reshaping access to cell therapies in the Middle East. With a GMP facility in Abu Dhabi set to locally manufacture CAR-T treatments, this decentralized approach aims to cut costs, increase access, and support patient-centric care across the region.

This story highlights real-world applications of GMDP Academy modules on translational medicine, regulatory strategy, and health equity—and provides a valuable case study for future leaders in medicines development [1, 2].

👉 [Read the full article](#)



## BURNOUT ISN'T INEVITABLE: GMDP ACADEMY TRAINS PHARMA LEADERS TO THRIVE



Nearly half of pharma professionals report emotional exhaustion, yet support for those outside clinical roles—like regulatory, clinical, and medical affairs leaders—remains limited. Burnout isn't just personal; it affects ethical decision-making, leadership, and organizational performance.

This article explores the pressures behind pharma burnout and how GMDP Academy's Leadership in Medicines Development module offers a practical, targeted solution. Through real-world strategies, emotional intelligence, and personal action planning, Module 7 helps professionals lead effectively—without burning out [3,4,5,6].

👉 [Read the full article here.](#)

# NAVIGATING THE LIFE SCIENCES JOB MARKET IN 2025: SKILLS, SHIFTS, AND STRATEGIC ADAPTATION

As 2025 unfolds, the life sciences job market reflects a complex blend of cautious optimism and structural change. While hiring remains slow in the West—especially following biotech sector contractions—markets in APAC, including Singapore, Shanghai, and Bengaluru, are experiencing rapid growth and recruitment activity. Across regions, one thing is clear: success now hinges not just on technical expertise but on digital fluency, regulatory insight, and the ability to lead across disciplines.

This article examines the evolving employment landscape, the emergence of hybrid roles like AI Drug Discovery Lead and Digital Health Integration Specialist, and the specific skills top employers are prioritizing—from Python and regulatory strategy to Veeva and stakeholder engagement.



Explore how the GMDP Academy builds key skills in clinical trials, digital health, and regulatory affairs. [7,8]

👉 [Read the full article.](#)

## AI-DISCOVERED RENTOSERTIB ADVANCES TO PHASE 2A



For the first time, an AI-discovered drug—Rentosertib—has reached Phase 2a, marking a major milestone in real-world clinical impact. Developed for idiopathic pulmonary fibrosis (IPF) by Insilico Medicine, Rentosertib was both designed and target-identified using AI. The results: promising lung function improvements and strong tolerability in early trial data, published June 3 in Nature Medicine.

As AI reshapes the future of drug discovery, professionals must evolve alongside it. GMDP Academy's Module 8: Digital Technology in Medicines Development offers the tools to navigate the growing need for cross-functional fluency in AI-driven development [9,10,11].

👉 [Read the full article.](#)

# EU PHARMA REFORM: WHAT THE 2025 ‘PHARMA PACKAGE’ MEANS FOR MEDICINES DEVELOPMENT

On June 4, 2025, the Council of the European Union approved its position on the landmark pharma package—the most significant update to EU pharmaceutical legislation in over two decades. Designed to improve access, reduce regulatory burdens, and boost industry competitiveness, the package introduces changes to data protection, market exclusivity, environmental standards, and supply chain obligations.

For professionals in regulatory affairs, medical affairs, and clinical strategy, these changes could alter approval timelines, incentivize broader product launches, and increase expectations for transparency and sustainability. As the package heads into negotiations with the European Parliament, GMDP Academy offers flexible, module-based training to help you adapt.



Modules 5, 6, and 7 cover evolving EU regulations, strategic medical affairs, and leadership through regulatory change—equipping you to stay ahead in a shifting landscape [12, 13, 14].

👉 [Read the full article here and apply today.](#)

## POWERING PROGRESS WITH PRINCIPLES



As AI rapidly transforms healthcare, ethical leadership is more urgent than ever. The National Academy of Medicine’s new AI Code of Conduct sets six guiding commitments to ensure fairness, safety, and public trust in health technology.

GMDP Academy’s Module 8: Digital Technology in Medicines Development aligns with these values—offering practical training on digital tools, patient-centered design, digital ethics, and risk management [4, 15]. Enrollment is now open.

Ready to lead in the digital age? Want to access the new AI Code of Conduct? 👉 [Read more here.](#)

# SAFEGUARDING SCIENCE: REGULATORY AFFAIRS, DRUG SAFETY, AND MEDICINES DEVELOPMENT

In today's high-stakes environment for drug and biologics development, breakthrough science is only half the story. The other half? Navigating an increasingly complex regulatory landscape where safety, compliance, and strategy converge.

As the European Union advances its sweeping pharma package reform and global regulators tighten expectations around transparency-



and risk, life sciences professionals must be equipped to lead—not just follow—across the full regulatory lifecycle.

That's where Module 5: Regulatory Affairs, Drug Safety and Pharmacovigilance from the GMDP Academy comes in. Continue reading below to access your guide to regulatory complexity.

## MODULE 5: REGULATORY AFFAIRS, DRUG SAFETY AND PHARMACOVIGILANCE

Running from June 30 to August 10, 2025, this six-week, online module provides essential knowledge and skills for professionals responsible for bringing medicines to market safely and efficiently.

Participants will explore the regulatory systems that govern drug development globally—including FDA, EMA, and ICH guidance—and learn how to integrate safety and risk management into product strategy from day one.

**Dates:** June 30 –  
August 10, 2025

**Format:** 100% online  
(asynchronous  
learning + live expert-  
led webinars)

**Effort:** 5–12  
hours/week

**Tuition:** \$2,500 USD

Join professionals from around the  
world in mastering the science of  
regulation and the art of safeguarding  
patients.

 **Apply now**

# REFERENCES

1. Abbott, J. (2025, April 15). Burjeel and Caring Cross team to optimize CAR-T production in UAE. BioProcess Insider. <https://www.bioprocessintl.com/deal-making/burjeel-and-caring-cross-team-to-optimize-car-t-production-in-uae>
2. Silva, H., Stonier, P. D., Kerpel-Fronius, S., & Dubois, D. J. (Eds.). (2021). Grand challenges in pharmaceutical medicine: Competencies and ethics in medicines development. *Frontiers in Pharmacology*. <https://doi.org/10.3389/fphar.2021.789666.986-8>
3. Dunleavy, K. (2023, May 25). Biopharma staffers exhausted and susceptible to burnout, report says. Fierce Pharma. <https://www.fiercepharma.com/pharma/pharma-workers-more-exhausted-and-susceptible-burnout-report>
4. GMDP Academy. (2024). GMDP Academy Offerings 2024/2025. <https://info.gmdpacademy.org/course-catalog>
5. Hayes, J. (2025, March 17). Employee burnout: The hidden threat costing companies millions. *Forbes*. <https://www.forbes.com/sites/julianhayesii/2025/03/17/employee-burnout-the-hidden-threat-costing-companies-millions/>
6. Saraceno, N. (2024, November 20). Key challenges facing the pharma industry in 2025. *Pharmaceutical Commerce*. <https://www.pharmaceuticalcommerce.com/view/challenges-the-pharma-industry-2025>
7. Blended e-learning and certification for medicines development professionals: Results of a 7-year collaboration between King's College, London and the GMDP Academy, New York. *Frontiers in Pharmacology*, 15, 1417036. <https://doi.org/10.3389/fphar.2024.1417036>
8. Clinical trials in human medicines | European Medicines Agency. (n.d.). <https://www.ema.europa.eu/en/human-regulatory-overview/research-development/clinical-trials-human-medicines>
9. Research, C. F. D. E. A. (2024, May 2). CDER Quantitative Medicine Center of Excellence (QM COE). U.S. Food And Drug Administration. <https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/cder-quantitative-medicine-center-excellence-qm-coe>
10. Xu, Z., Ren, F., Wang, P., et al. (2025). A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial. *Nature Medicine*. <https://www.nature.com/articles/s41591-025-03743-2>
11. Global Times. (2025, June 3). World's fastest AI-discovered medicine enters phase 2a trial, marking breakthroughs in drug development. <https://www.globaltimes.cn/page/202506/1335390.shtml>
12. Xinhua News Agency. (March 2025). AI terminal push set to empower China's new tech consumption, citing IDC.
13. Council of the European Union. (2025, June 4). 'Pharma package': Council agrees its position on new rules for a fairer and more competitive EU pharmaceutical sector. <https://www.consilium.europa.eu/en/press/press-releases/2025/06/04/pharma-package-council-agrees-its-position-on-new-rules-for-a-fairer-and-more-competitive-eu-pharmaceutical-sector/>, Council of the EU, 2025a
14. Council of the European Union. (2025, June 2). Proposal for a Regulation of the European Parliament and of the Council laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing rules governing the European Medicines Agency (ST 9286/2025 INIT). <https://data.consilium.europa.eu/doc/document/ST-9286-2025-INIT/en/pdf>, Council of the EU, 2025b
15. Council of the European Union. (2025, June 2). Proposal for a Directive on the Union code relating to medicinal products for human use (ST 9285/2025 INIT). <https://data.consilium.europa.eu/doc/document/ST-9285-2025-INIT/en/pdf>, Council of the EU, 2025c
16. National Academy of Medicine. (2025). An artificial intelligence code of conduct for health and medicine: Essential guidance for aligned action (L. Adams, E. Fontaine, M. Matheny, & S. Krishnan, Eds.). The National Academies Press. <https://doi.org/10.17226/29087>

## Thanks for reading!

The GMDP Academy Newsletter is published twice monthly and is compiled by the following:

**Media Manager:** Whitney English

**Editorial Board:** Pravin Chopra, Jacob Coots

**Operations Office:** Amanda Schmitt, Gustavo Silva, Kit Vale

## CONTACT US:



420 Lexington Ave. Ste. 300  
New York, NY 10170

(332) 333-2438